Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

2.

TBC1D16 is a Rab4A GTPase activating protein that regulates receptor recycling and EGF receptor signaling.

Goueli BS, Powell MB, Finger EC, Pfeffer SR.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15787-92. Epub 2012 Sep 10.

3.

Targeting melanoma: unusual epigenetics reveals the dynamic rewiring of metastatic cells.

Vizoso M, Esteller M.

Epigenomics. 2015 Oct;7(7):1079-81. doi: 10.2217/epi.15.67. Epub 2015 Nov 6. No abstract available.

PMID:
26541242
4.

DNA methylation plasticity contributes to the natural history of metastasis.

Vizoso M, Esteller M.

Cell Cycle. 2015;14(18):2863-4. doi: 10.1080/15384101.2015.1076300. No abstract available.

5.

Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.

Gong F, Guo Y, Niu Y, Jin J, Zhang X, Shi X, Zhang L, Li R, Chen L, Ma RZ.

Oncotarget. 2017 Jan 3;8(1):315-328. doi: 10.18632/oncotarget.13324.

6.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

7.

Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.

Bujko M, Kober P, Rusetska N, Wakuła M, Goryca K, Grecka E, Matyja E, Neska J, Mandat T, Bonicki W, Siedlecki JA.

J Neurooncol. 2016 Dec;130(3):473-484. Epub 2016 Sep 10.

8.

A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.

Huang M, Qi TF, Li L, Zhang G, Wang Y.

Cancer Res. 2018 Sep 15;78(18):5431-5445. doi: 10.1158/0008-5472.CAN-17-3811. Epub 2018 Aug 2.

9.

An integrated approach to uncover drivers of cancer.

Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D.

Cell. 2010 Dec 10;143(6):1005-17. doi: 10.1016/j.cell.2010.11.013. Epub 2010 Dec 2.

10.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.

Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.

11.

Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types.

Rodger EJ, Chatterjee A, Stockwell PA, Eccles MR.

Clin Epigenetics. 2019 Aug 5;11(1):114. doi: 10.1186/s13148-019-0710-5.

12.

Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.

Mehrotra A, Saladi SV, Trivedi AR, Aras S, Qi H, Jayanthy A, Setaluri V, de la Serna IL.

Arch Biochem Biophys. 2014 Dec 1;563:125-35. doi: 10.1016/j.abb.2014.07.004. Epub 2014 Jul 12.

13.

DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.

Venza M, Visalli M, Catalano T, Beninati C, Teti D, Venza I.

Hum Pathol. 2017 Feb;60:137-146. doi: 10.1016/j.humpath.2016.10.018. Epub 2016 Nov 4.

PMID:
27825810
14.
15.

Epigenetic regulation in human melanoma: past and future.

Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME.

Epigenetics. 2015;10(2):103-21. doi: 10.1080/15592294.2014.1003746. Review.

16.

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S.

PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.

17.

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers.

Yun J, Song SH, Park J, Kim HP, Yoon YK, Lee KH, Han SW, Oh DY, Im SA, Bang YJ, Kim TY.

Lab Invest. 2012 Jul;92(7):1033-44. doi: 10.1038/labinvest.2012.61. Epub 2012 Apr 16. Erratum in: Lab Invest. 2013 Oct;93(10):1165.

18.

RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ.

Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.

19.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.

PMID:
25079330
20.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.

Bonnevaux H, Lemaitre O, Vincent L, Levit MN, Windenberger F, Halley F, Delorme C, Lengauer C, Garcia-Echeverria C, Virone-Oddos A.

Mol Cancer Ther. 2016 Jul;15(7):1460-71. doi: 10.1158/1535-7163.MCT-15-0496. Epub 2016 May 12.

Supplemental Content

Support Center